New book by Larry Connors Click here Improve your trading - See how
"We are delighted to have The Dilenschneider Group on-board to lead our newly implemented investor and media relations effort at a pivotal time in the company's development," said Dr. Stephen Barnhill, Chairman and CEO of Health Discovery Corporation. "The Dilenschneider Group is a highly respected corporate communications firm and we welcome their expertise to effectively communicate the Company's exciting corporate achievements," said Dr. Barnhill.
"We are pleased to be representing Dr. Barnhill and the Company," said Robert Dilenschneider, Chairman of The Dilenschneider Group. "They are at the forefront in the development of an entirely new and revolutionary approach to diagnostic and personalized medicine, and we welcome this opportunity to communicate the Company's successes," Mr. Dilenschneider said.
HDC recently entered into royalty-bearing licenses for its new urine-based prostate cancer test to Quest Diagnostics Incorporated (NYSE: DGX) and Abbott Laboratories (NYSE: ABT) for development and commercialization. HDC also entered into royalty-bearing licenses for its tissue biopsy-based prostate cancer test with Abbott Laboratories (NYSE: ABT) and Clarient Inc. (Nasdaq: CLRT) for development and commercialization. HDC has also partnered with Pfizer Inc. (NYSE: PFE) for use of HDC's SVM and SVM-RFE pattern recognition technology.
A scientific paper on the association of these four genes with prostate cancer was recently published in the peer-reviewed journal, UroToday International, in its August 2009 issue. The combined results of the double-blind clinical validation studies demonstrated that the new gene-based molecular diagnostic test for prostate cancer achieved a Sensitivity of 90% for correctly identifying the presence of Grade 3 or higher prostate cancer cells, and a Specificity of 97% for correctly identifying non-cancer cells (normal and BPH), representing an overall test accuracy of 93%.
HDC's new prostate cancer tests are based on a unique and patent protected combination of four genes that have been shown to accurately identify the presence of Grade 3 or higher prostate cancer cells in prostate tissue and urine. The association of these four genes with prostate cancer was discovered by Health Discovery Corporation using their patented SVM and SVM-RFE pattern recognition technology.
About Health Discovery Corporation
Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see www.healthdiscovercorp.com.
About The Dilenschneider Group
The Dilenschneider Group is a corporate strategic consulting and investor and public relations firm headquartered in New York City and has offices in Chicago and Washington, DC. For more information, see www.dilenschneider.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements relating to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop or commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company's Securities and Exchange Commission filings.
All forward-looking statements and cautionary statements included in this document are made as of the date hereof based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward-looking statement or cautionary statement.
SOURCE: Health Discovery Corporation
For Health Discovery Corporation Matthew Swetonic, 212-922-0900 Media Relations mswetonic@dgi-nyc.com or Tom Gallagher, 212-922-0900 Investor Relations tgallagher@dgi-nyc.com
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
